Caption Management, LLC Amylyx Pharmaceuticals, Inc. Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.62 - $2.71 $1,944 - $3,252	1,200 New	1,200 $2,000
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $510,029 - $780,045	-42,256 Reduced 47.34%	47,000 $691,000
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $944,788 - $1.23 Million	52,256 Added 141.23%	89,256 $1.63 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $776,260 - $1.16 Million	37,000 New	37,000 $798,000
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $457,973 - $825,687	-26,704 Reduced 38.34%	42,947 $1.21 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $225,940 - $657,371	32,984 Added 89.96%	69,651 $1.34 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $471,170 - $1.21 Million	36,667 New	36,667 $472,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.